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Abstract
Context—Inhaled nanoparticles can migrate to the brain via the olfactory bulb, as demonstrated 
in experiments in several animal species. This route of exposure may be the mechanism behind the 
correlation between air pollution and human neurodegenerative diseases, including Alzheimer’s 
disease and Parkinson’s disease.
Objectives—This manuscript aims to (1) estimate the dose of inhaled nanoparticles that deposit 
in the human olfactory epithelium during nasal breathing at rest and (2) compare the olfactory 
dose in humans with our earlier dose estimates for rats.
Materials and methods—An anatomically-accurate model of the human nasal cavity was 
developed based on computed tomography scans. The deposition of 1–100 nm particles in the 
whole nasal cavity and its olfactory region were estimated via computational fluid dynamics 
(CFD) simulations. Our CFD methods were validated by comparing our numerical predictions for 
whole-nose deposition with experimental data and previous CFD studies in the literature.
Results—In humans, olfactory dose of inhaled nanoparticles is highest for 1–2 nm particles with 
approximately 1% of inhaled particles depositing in the olfactory region. As particle size grows to 
100 nm, olfactory deposition decreases to 0.01% of inhaled particles.
Discussion and conclusion—Our results suggest that the percentage of inhaled particles that 
deposit in the olfactory region is lower in humans than in rats. However, olfactory dose per unit 
surface area is estimated to be higher in humans due to their larger minute volume. These dose 
estimates are important for risk assessment and dose-response studies investigating the 
neurotoxicity of inhaled nanoparticles.
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INTRODUCTION
Inhalation of nanoparticles from air pollution and occupational exposure may cause 
neurodegeneration and brain damage (Calderon-Garciduenas et al., 2002; Sunderman, 
2001). The route taken by inhaled nanoparticles to reach the brain is unclear, but there is 
increasing evidence that metal nanoparticles depositing in the olfactory region in the nasal 
cavity can migrate to the brain along the olfactory bulb (Hopkins et al., 2014; Oberdorster et 
al., 2004). Although this nose-to-brain route of exposure has not been confirmed in humans, 
it has been demonstrated in non-human primates (Dorman et al., 2006). Evidence suggests 
that a Parkinson-like neurological syndrome in workers exposed to manganese-containing 
welding fumes may be associated with nose-to-brain transport of manganese particles 
(Antonini et al., 2006). As part of the investigation of this potential route of exposure, it is 
essential to quantify the dose of inhaled nanoparticles that deposit in the olfactory region in 
both humans and rats.
In vivo measurements of olfactory dose in humans are challenging due to ethical concerns 
and the difficulty of distinguishing particles deposited in the olfactory region from those 
deposited elsewhere in the nose. In vitro studies using nasal replicas are also challenging 
because they require sectional analysis to distinguish olfactory from non-olfactory 
deposition (Schroeter et al., 2015). Although both in vivo and in vitro experiments are 
feasible, currently there are no publications in the literature reporting experiments that 
quantify nanoparticle deposition in the human olfactory region.
Computational models of airflow and particle transport represent an attractive tool to 
evaluate nanoparticle deposition in the human olfactory region. The location of the various 
nasal epithelial types, including the olfactory epithelium, can be mapped onto a 3-
dimensional reconstruction of the nasal passages (Figure 1). Computational fluid dynamics 
(CFD) can be used to simulate airflow patterns and to quantify the dose of inhaled particles 
deposing in the olfactory region. Another advantage of computational methods is that, once 
the anatomic model is created and the numerical methods validated, several particle sizes 
and breathing rates can be simulated with minimal additional cost. To the best of our 
knowledge, the only estimates of nanoparticle deposition in the human olfactory region to 
date were reported by Shi and coworkers (2008) (Shi et al., 2008). They used a 
computational model to simulate nasal airflow and particle transport and predicted that 
olfactory deposition is highest for 1–2 nm particles with 0.5% of inhaled particles depositing 
in the olfactory region. Importantly, differences between humans and rats regarding the 
olfactory dose of inhaled nanoparticles have not yet been reported in the literature, despite 
the fact that toxicological studies often use experiments in laboratory animals to infer the 
risk inhaled nanoparticles pose to humans.
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In a previous study, we investigated olfactory deposition of 1–100 nm particles in a 
computational model of the nasal cavity of an 18-week-old F344 rat (Garcia & Kimbell, 
2009). Olfactory deposition was maximal for 3- to 4-nm particles, with 6–9% of inhaled 
material depositing in the olfactory region. The present manuscript extends our previous 
efforts by estimating the olfactory dose of inhaled nanoparticles in humans and by 
comparing the olfactory dose in humans vs. rats.
METHODS
Anatomic models
Nanoparticle deposition in the human nasal cavity was simulated in the nasal anatomies of 
two healthy adults (Figure 1). Model 1, which has higher anatomic resolution (voxel size of 
0.39 mm × 0.39 mm × 0.70 mm), was built from CT scans of a 37 year-old woman (Garcia 
et al., 2009). Model 2, which has lower anatomic resolution (3-mm spacing between coronal 
sections), was built from MRI scans of a 53 year-old male (Subramanian et al., 1998). The 
geometry of model 2 has been used in several experimental studies (Garcia et al., 2009; 
Kelly et al., 2004a; Kelly et al., 2004b; Schroeter et al., 2015; Shah et al., 2015; Swift, 1991; 
Zwartz & Guilmette, 2001) and computational studies (Kimbell et al., 2007; Schroeter et al., 
2006; Xi et al., 2015; Xi & Longest, 2008) of particle deposition in the human nose. Thus, 
model 2 was included in this study solely for experimental validation of our numerical 
methods and for comparison with previous computational studies. Olfactory dose of inhaled 
nanoparticles is reported only for model 1. To investigate the effect of olfactory surface area 
on olfactory dose estimates, three variations of model 1 were investigated. Models 1A, 1B, 
and 1C had the exact same geometry, except for the extent of the region mapped as olfactory 
epithelium on the model surface (Figure 1).
The olfactory region of the nasal cavity is the part of the nasal passages covered by olfactory 
epithelium. At present, olfactory epithelium is primarily identified histologically by its 
distinctive cellular composition and structure (Harkema et al., 2006), including its brownish-
yellow color compared to the pink color of the surrounding respiratory epithelium (Jackson, 
1960). Experimental imaging studies suggest that it is possible to visualize the location of 
the olfactory epithelium in vivo using ultra-high resolution optical coherence tomography 
(Cobb et al., 2010), or by performing single photon emission computed tomography 
(SPECT) after nasal administration of a thallium-201 saline solution (Shiga et al., 2011). 
However, the most precise location and extent of this epithelial type is currently obtained 
from serial histological sections of nasal specimens. Thus, the location and extent of the 
olfactory epithelium was mapped by Schroeter and colleagues (5) onto the walls of Model 1 
based on the descriptions and figures published by Lang (1989) (see Model 1A in Figure 1).
Due to the uncertainty of the precise location of the olfactory epithelium, and also to 
facilitate comparison of dose estimates with previous publications, two variants of this 
model were investigated. Models 1B and 1C had half the olfactory surface area and twice 
the olfactory surface area of the original model, respectively. The olfactory surface areas of 
models 1A, 1B, and 1C are respectively 11.2 cm2, 5.6 cm2, and 22.0 cm2. Given that the 
total surface area (nasal cavity and nasopharynx) was 201.6 cm2 in model 1, the olfactory 
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region corresponded to 5.5%, 2.8%, and 10.9% of the total surface area in models 1A, 1B, 
and 1C, respectively.
Computational Methods
Computational fluid dynamics was used to simulate airflow and nanoparticle deposition in 
the nasal cavity and, more specifically, the olfactory region. Computational meshes with 
approximately 5 million hybrid cells (tetrahedral cells with 4 prism layers near the walls) 
were used. CFD simulations were conducted in Fluent™ 14.0 (ANSYS Inc., Lebanon, NH). 
Inspiratory airflow was modeled as laminar and at steady-state. Since diffusional transport 
mechanisms dominate for 1–100 nm particles, an Eulerian approach was used for particle 
transport. In this approach, the trajectories of individual particles are not computed; instead, 
inhaled nanoparticles are modeled as a uniform mixture of particles and air, much as gas 
transport is modeled. Details regarding the simulations are described in the Appendix A.
To assess the effects of particle size and airflow rate on deposition, simulations were 
performed for a series of particle sizes and inhalation rates. The resting minute volume of an 
adult human is approximately 7.5 L/min for cyclic flow, which corresponds to an average 
inspiratory flow of 15 L/min. We therefore investigated three different steady-state airflow 
rates, namely, 15 L/min, 22.5 L/min and 30 L/min, corresponding to 1x, 1.5x, and 2x the 
resting flow rate. This range of flow rates includes the average worker rate of 9.6 m3/8-hr-
day = 20 L/min (ICRP66, 1994).
Particle diffusivity is affected by particle shape, but irregular shape seldom produces more 
than a two-fold change in any property (Hinds, 1999), unless the particles of interest are 
highly elongated. Particle diffusivity becomes orientation-dependent with elongated shape, 
in which case particle rotation must be modeled (Dastan et al., 2014). For this project, all 
particles were assumed spherical in shape. Appropriate diffusion coefficients for spherical 
particles were computed for each particle size as described by Hinds (1999) (Table 1). Ten 
different particle sizes were used ranging from 1 to 100 nm (Table 1). These particle sizes 
were chosen so that data points are uniformly spaced in a log-log plot.
Curve Fitting
Nasal deposition efficiency was plotted against particle size for each flow rate. Curves were 
fitted to the data so that deposition could be estimated for other sets of parameters that were 
not simulated. Ingham (Ingham, 1991) proposed that nanoparticle deposition in the nose is a 
function of two non-dimensional parameters: Schmidt number (Sc = ν/Dp, where ν is the 
kinematic viscosity of air and Dp is the particle diffusivity; (Hinds, 1999)) and Δ (a diffusion 
parameter defined as Δ = DpL/(4 U R2), where L is a characteristic length of the geometry, 
U is average inlet velocity and R is airway radius; (Zhang & Martonen, 1997)). Because a 
single nasal geometry was investigated, the parameters L and R were constant, so that nasal 
deposition efficiency was a function only of the particle diffusivity Dp and the average 
velocity U. Since U is proportional to the airflow rate Q, namely U ~ Q/R2, nasal deposition 
in our model was a function of Dp and Q alone. Total nasal deposition (η) was fitted with the 
equation (Cheng, 2003)
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where Dp is in cm2/s, Q is in L/min, and a, b, and c are fitted parameters. Note that this 
functional form is in agreement with the requirement that 0 ≤ η ≤ 1. All curve-fitting 
analyses were made using SigmaPlot™ 12.0 (Systat Software, Inc., San Jose, CA).
The olfactory fraction of total nasal deposition (FO) was also computed from the CFD 
simulations and plotted against particle size. Curves were fitted to the simulation data using 
the formula
(2)
where FO is the percentage of the particles depositing in the nose that deposited in the 
olfactory region and a, b, c, and d are fitted parameters. Once the total nasal deposition 
efficiency (η) and the olfactory fraction (FO) were calculated, the olfactory deposition 
efficiency (ηO) was obtained by
(3)
where ηO is the fraction of inhaled particles that deposit in the olfactory region.
Hotspots of particle deposition are of particular interest in toxicology and risk assessment. 
To describe the spatial patterns of particle deposition, the locations of deposited particles 
were visualized using Fluent™ 14.0 and Fieldview™ 13.2 (Intelligent Light, Rutherford, NJ). 
To characterize the effect of particle size on the spatial distribution of deposited particles, 
the wall mass flux was averaged along the perimeter of coronal cross-sections and plotted as 
a function of the distance from the nostrils for different particle sizes.
Olfactory Deposition in Rats
Garcia and Kimbell (2009) used the computational methods described above to estimate the 
olfactory dose of inhaled nanoparticles for an 18-week-old male F344 rat (body mass = 
315g). These estimates for the rat are used here for comparison with humans.
RESULTS
Deposition of Nanoparticles in the Human Nose
Total nasal deposition of nanoparticles was predicted to decrease with increasing particle 
size and airflow rate (Figure 2). Total deposition in the human nose was estimated to be 
approximately 65% for 1 nm particles, 4% for 13 nm particles, and 0.3% for 100 nm 
particles during resting breathing (Q = 15 L/min). Although the total nasal deposition 
efficiency decreases with increasing particle size, among the particles that do deposit, the 
larger nanoparticles have a higher probability of depositing in the olfactory region (Figure 
3). Olfactory deposition was predicted to be maximal for 1–2 nm particles, with 
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approximately 1% of inhaled particles depositing in the olfactory region. For particles larger 
than 3 nm, olfactory deposition decreased with increasing particle size (Figure 4).
The spatial distribution of deposited particles in the human nose was examined for 3 and 30 
nm particles (Figure 5). Hotspots of deposition of 3 nm particles were observed on the nasal 
vestibule, anterior septum, anterior edge of the inferior and middle turbinates, inferior 
margin of the middle and superior turbinates, and posterior wall of the nasopharynx. Higher 
deposition in the anterior nose relative to the posterior nose is further illustrated by 
considering wall flux averaged over the perimeter of serial coronal sections between the 
nostrils and the nasopharynx (Figure 6). A similar anterior-to-posterior gradient was 
observed for the wall fluxes of 30 nm particles, but regional differences were much smaller 
than for 3 nm particles. In other words, larger nanoparticles had a more uniform deposition 
throughout the nasal passages, which explains why, for 10–100 nm nanoparticles, the 
olfactory fraction of deposited particles is similar to the percentage of surface area covered 
by olfactory epithelium (5.5% in Model 1A) (Figure 3).
Curve Fits
The best fit for total nasal deposition was obtained with equation (1) with a = 28.3 ± 0.7, b = 
0.659 ± 0.002, and c = 0.502 ± 0.007, which provided a correlation coefficient of r = 0.9999 
(Figure 2). The high value of the correlation coefficient implies that equation (4) accurately 
describes how airflow rate and particle size affect total nasal deposition. The best fit for 
olfactory fraction of deposited particles was obtained with equation (2) with a = 0.046 ± 
0.001, b = 19 ± 11, c = 0.42 ± 0.05, and d = 0.60 ± 0.16, which provided a correlation 
coefficient of r = 0.946 (Figure 3). The fitting curves for olfactory deposition (ηO) were 
obtained via ηO = FO η (equation (3)) using the fitted curves for total nasal deposition (η) 
and olfactory fraction (F0). Therefore, the curves in Figure 4 were not fitted to CFD 
olfactory deposition but are rather estimates from the product of curves fitted to the total 
deposition and olfactory fraction data.
Effect of olfactory surface area
Given that the boundaries of the olfactory region in Model 1A were based on a textbook 
(Lang, 1989), rather than on actual measurements, the size of the olfactory region was varied 
to investigate its effect on dose estimates (Figure 1). Olfactory surface area had a significant 
effect on the olfactory dose estimates, with larger olfactory regions resulting in greater 
olfactory depositions (Figure 7A). Due to the more uniform spatial deposition of 10 to 100 
nm particles (Figures 5 and 6), olfactory deposition was nearly proportional to olfactory 
surface area in this particle size range (Figure 7B). In contrast, the effect of olfactory surface 
area was non-linear for the smallest nanoparticles. For example, olfactory deposition of 1-
nm particles was 3.3 times greater in model C than in model A, thus exceeding the 2-fold 
difference in olfactory surface area between these models.
Experimental validation
There are no experimental studies in the literature that report olfactory dose of inhaled 
nanoparticles in humans. However, we can validate our results for total nasal deposition by 
comparing them to experimental measurements (Figure 8). Total nasal deposition of inhaled 
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nanoparticles has been studied experimentally in vivo (Cheng et al., 1996; Cheng et al., 
1996) and in vitro using nasal replica casts based on medical images (Cheng et al., 1995; 
Kelly et al., 2004b; Swift et al., 1992). In addition, previous CFD studies have studied 
nanoparticle transport in the human nose computationally. Several in vitro and in silico 
studies were based on the nasal geometry of model 2 (Ge et al., 2012; Ghalati et al., 2012; 
Shi et al., 2008; Xi & Longest, 2008; Zamankhan et al., 2006). As illustrated in Figure 8, our 
CFD results are in good agreement with these previous experimental and computational 
studies.
Humans vs. Rats
Nasal and olfactory deposition of 1–100 nm particles are compared in humans vs. rats in 
Figure 9. Nasal deposition efficiency of nanoparticles is greater in rats (Figure 9A). This is 
explained by their narrower nasal airways, which reduce the distance particles have to 
diffuse before they hit a wall. Olfactory deposition efficiency is also higher in the rat (Figure 
9B), which is partially due to the narrower airways in the rat, but also due to the 
proportionally larger olfactory region in rodents (the olfactory epithelium covers 40% of the 
nasal cavity in the rat, but only 5.5% in the human) (Garcia & Kimbell, 2009). Olfactory 
deposition efficiency is only 2-fold higher in rats as compared to humans for 1-nm particles, 
but the rat-to-human ratio increases to 25-fold for 10-nm to 100-nm particles (Figure 9C).
Finally, let us illustrate how the olfactory deposition efficiency may be used in risk 
assessment studies. In polluted urban centers, air concentration of nanoparticles is about 
10,000 particles/cm3 (Kittelson et al., 2004). For simplicity, we assume a uniform 
distribution of particle sizes in the range of 1–100 nm, so that for a given particle size (e.g., 
5 nm particles), the nanoparticle concentration is 100 particles/cm3. Given the differences in 
minute volumes (7.5 L/min in humans vs. 0.288 L/min in rats) and olfactory deposition 
efficiency of 5-nm particles (0.46% in humans vs. 6.0% in rats), the number of 5-nm 
particles that deposit in the olfactory region is estimated to be 5.0 × 106/day in humans and 
2.5 × 106/day in rats. This shows that the number of particles reaching the olfactory region is 
only about 2 times greater in humans than rats, despite the 26-fold higher inhalation rate in 
humans. Taking into account the olfactory surface areas (11.2 cm2 in humans vs. 7.4 cm2 in 
rats), olfactory dose per unit surface area is estimated to be 4.5 × 105 particles/day/cm2 in 
humans and 3.4 × 105 particles/day/cm2 in rats. Thus, despite the higher olfactory deposition 
efficiency in rats, the olfactory dose per unit surface area for 5-nm particles is higher in 
humans due their higher inhalation rate. The olfactory dose per unit surface area has a 
complex dependency on particle size, with higher olfactory doses in humans in the 1–7 nm 
size range, but similar doses in rats and humans in the 7–100 nm range (Figure 9D).
DISCUSSION
Nose-to-brain translocation of nanoparticles is a topic of great interest due to the toxic 
effects some nanomaterials have on the central nervous system (Block & Calderon-
Garciduenas, 2009; Lucchini et al., 2012). The existence of the nose-to-brain pathway of 
particle transport has been demonstrated by inhalation experiments in laboratory animals, 
which observed that nanoparticles depositing on the olfactory epithelium can migrate to the 
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brain along the olfactory bulb (Balasubramanian et al., 2013; Elder et al., 2006; Hopkins et 
al., 2014; Kao et al., 2012; Moshkin et al., 2014; Oberdorster et al., 2004; Sunderman, 2001; 
Yu et al., 2007). Experimental studies instilling an aqueous solution of nanoparticles into the 
nasal cavity of rodents have corroborated this nose-to-brain migration of nanoparticles (Liu 
et al., 2014; Wang et al., 2008). Once toxic nanoparticles reach the brain, multiple adverse 
effects can be observed, including inflammation, oxidative stress, and neurodegeneration 
(Calderon-Garciduenas et al., 2014; Liu et al., 2014). Air pollution and occupational 
exposure are likely the two main sources of exposure to airborne nanoparticles.
Air pollution is of great concern because children living in polluted urban environments 
(e.g., Mexico City) have been shown to have neuroinflammation, neurodegeneration, and 
delays in cognitive development as compared to children who live a less polluted city 
(Calderon-Garciduenas et al., 2008; Calderon-Garciduenas et al., 2008; Calderon-
Garciduenas et al., 2014). Strong evidence suggests that ultrafine particles in air pollution 
can reach the brain through the olfactory pathway, and that this is a key mechanism for the 
neurodegenerative effects of air pollution (Block & Calderon-Garciduenas, 2009; Calderon-
Garciduenas et al., 2002; Calderon-Garciduenas et al., 2003; Calderon-Garciduenas et al., 
2008). Also, it has been suggested that Alzheimer’s and Parkinson’s diseases may be 
associated with airborne agents entering the brain through the olfactory pathway, but this 
remains speculative (Block & Calderon-Garciduenas, 2009; Doty, 2008). Occupational 
exposure to inhaled nanoparticles is also of great concern. Inhaled metal nanoparticles have 
several toxic effects in the nasal cavity, including loss of olfactory acuity (Sunderman, 
2001). In particular, workers exposed to welding fumes rich in manganese sometimes 
develop a Parkinson-like neurological disease (Antonini et al., 2006). Finally, we must 
mention that there is growing interest in the nose-to-brain pathway as a route for delivering 
drugs to the brain (Illum, 2000; Mistry et al., 2009; Mittal et al., 2014; Sood et al., 2014).
Nasal deposition of inhaled nanoparticles has been extensively studied in humans through in 
vivo experiments in healthy volunteers (Cheng et al., 1996; Cheng et al., 1996), in vitro 
experiments in nasal replica casts based on cadavers or imaging of live subjects (Cheng et 
al., 1995; Golshahi et al., 2010; Gradon & Yu, 1989; Kelly et al., 2004b; Swift et al., 1992), 
and computational models (Ge et al., 2012; Ghalati et al., 2012; Inthavong et al., 2011; 
Martonen et al., 2003; Shi et al., 2006; Shi et al., 2008; Si et al., 2013; Wang et al., 2009; Xi 
et al., 2012; Xi & Longest, 2008; Yu et al., 1998; Zamankhan et al., 2006; Zhang & 
Kleinstreuer, 2011). These studies have shown that nasal filtration of nanoparticles is 
governed by diffusion, with the smallest particles having the greatest diffusivity and 
therefore the greatest nasal deposition. The human nose filters less than 5% of 100-nm 
particles, but more than 80% of 1-nm particles during resting breathing (Cheng, 2003).
Recent computational studies investigated a myriad of topics related to nanoparticle 
deposition in the respiratory tract, including targeted olfactory deposition of 150 nm 
particles with a nebulization catheter for direct nose-to-brain drug delivery (Si et al., 2013), 
age-related changes in nasal deposition efficiency (Xi et al., 2012), how the exclusion of the 
paranasal sinuses from anatomic models affects dose estimates (Ge et al., 2012), and the 
accuracy of different numerical methods (Shi et al., 2006; Shi et al., 2008; Xi & Longest, 
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2008; Zhang & Kleinstreuer, 2011). However, the olfactory dose of inhaled 1–100 nm 
particles was not investigated in the majority of these studies.
To our knowledge, Shi et al. (2008) reported the only estimate of nanoparticle deposition in 
the human olfactory region previously available in the literature (Shi et al., 2008). These 
authors applied CFD to simulate nasal airflow and nanoparticle transport numerically. 
Olfactory deposition was predicted to be maximum at 0.55% of inhaled particles for 2 nm 
particles. In our study, olfactory deposition in Model 1A was 0.93% of inhaled 2 nm 
particles (Figure 4), which is almost twice as high as the olfactory dose estimated by Shi et 
al. (2008). Although Shi et al. (2008) did not explicitly mention the olfactory surface area of 
their CFD model, a visual comparison of Figure 1(b) in their paper with Figure 1 in this 
manuscript reveals that their CFD model had a much smaller olfactory region than our 
Model 1A, and possibly their olfactory surface area was closer to our Model 1B. Given that 
the olfactory dose is strongly dependent on the extent of the olfactory surface area (Figure 
7), we attribute any differences between our estimates of olfactory dose and the results 
reported by Shi et al. (2008) to differences in the surface area of the region mapped as 
olfactory epithelium on the CFD model and to inter-individual nasal anatomy differences.
This is the first study to compare the olfactory dose of inhaled nanoparticles in humans vs. 
rats. One strength of our study is that the same methods were used to simulate particle 
transport in humans and rats, thus allowing a consistent comparison of the olfactory dose in 
the two species. As expected based on the relationship between particle size and particle 
diffusivity, olfactory deposition efficiency was highest for the smallest particles in both 
humans and rats (Figure 9B). However, olfactory deposition efficiency was predicted to be 
substantially higher in rats than in humans. Olfactory deposition efficiency of 1-nm particles 
was predicted to be 2-fold higher in rats than in humans, with the rat-to-human difference 
increasing with particle size, to the point that olfactory deposition efficiency of 100-nm 
particles is 23-fold higher in rats than in humans (Figure 9C). However, due to the 26-fold 
higher inhalation rate in humans as compared to rats, the actual dose of nanoparticles 
deposited in the olfactory region was higher in humans in the 1–7nm size range. Olfactory 
dose of 7–100nm was similar in rats and humans (Figure 9D). One should note that the 
comparisons above refer to the average olfactory dose in humans and rats. Doses in other 
anatomic regions, including localized doses within the olfactory region, or the whole-nose 
average dose, may not follow the same pattern (see Appendix B).
In addition to our previous study of nanoparticle deposition in a rat model (Garcia & 
Kimbell, 2009), other CFD studies have also reported estimates of olfactory dose of 1–100 
nm in rodents, including two studies on rats (Jiang & Zhao, 2010; Schroeter et al., 2012) and 
one study on a mouse and a mole vole (Moshkin et al., 2014). Generally speaking, these 
studies reported that olfactory dose is maximum for 3–5 nm particles with approximately 6–
20% of inhaled particles in this size range depositing in the olfactory region of rodents. 
Interestingly, Moshkin and coauthors (2014) reported that olfactory deposition was lower in 
the subterranean mole vole, despite total nasal deposition being higher in that species. They 
interpreted the lower olfactory deposition in the subterranean mole vole as an adaption to 
habitation in an environment with dust excess aimed at decreasing nose-to-brain particle 
transport.
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Some limitations of our research methods should be noted. First, the extent of the olfactory 
surface area in Model 1A (11.2 cm2) was based on the anatomy book by Lang (1989), and 
may not reflect the exact extent of the olfactory region in the subject whose CT scans were 
used to develop the CFD model. Second, the Eulerian model used to compute particle 
transport in this study may under-predict nasal deposition for particle sizes greater than 50 
nm (Ge et al., 2012; Xi & Longest, 2008). However, previous research has shown that the 
Eulerian model is accurate for particle sizes < 50nm (Ge et al., 2012; Xi & Longest, 2008), 
which is the size range with the greatest olfactory deposition. Third, our simulations 
assumed that nasal airflow is laminar. This assumption is supported by experimental 
measurements of air velocity in nasal replicas which show that nasal airflow is mostly 
laminar for airflow rates below 30 L/min (Chung et al., 2006; Kelly et al., 2000), and by 
CFD studies comparing laminar vs. turbulent models which concluded that nasal airflow is 
mostly laminar for rest breathing (Shi et al., 2008; Xi & Longest, 2008). Finally, 
experimental studies have reported interindividual variation in total nasal deposition due to 
differences in nasal anatomy (Cheng et al., 1996; Cheng et al., 1995; Cheng et al., 1996; 
Golshahi et al., 2010). Likewise, olfactory dose is expected to vary among individuals. 
Therefore, our olfactory dose estimates, which were based on a single individual, may not be 
representative of average deposition in the larger population.
CONCLUSIONS
The dose of inhaled nanoparticles that deposit in the human olfactory region was estimated 
for particle sizes from 1 to 100 nm and inhalation rates from 15 to 30 L/min. Our 
simulations suggest that olfactory deposition is greatest for 1–2 nm particles with 
approximately 1% of inhaled particles of that size range depositing in the olfactory region. 
When compared to humans, rats have a higher olfactory deposition efficiency, which can be 
attributed to (a) the olfactory epithelium accounting for a larger percentage of the nasal 
surface area in rodents and (b) the narrower nasal passages in the rat. However, after taking 
into account the higher minute volume in humans, olfactory dose per unit surface area is 
greater in humans than in rats for 1–10 nm particles. The dosimetry data and fitted curves 
reported for humans in this manuscript and for rats in Garcia and Kimbell (2009) are 
expected to be useful in the risk assessment of inhaled nanoparticle toxicity.
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APPENDIX A
Conservation of mass and momentum for laminar incompressible flow is described, 
respectively, by the equations
where u⃗ = u⃗(x, y, z, t) is the velocity vector, t is time, ρ = 1.2 kg/m3 is air density, p is 
pressure, and μ = 1.8 × 10−5 Pa.s is air dynamic viscosity (White, 2008). The transport of 
nanoparticles in air is described by the convection-diffusion equation
where Cp = Cp(x, y, z, t) is the nanoparticle concentration in air and Dp is the mass-
diffusivity of nanoparticles in air (Hinds, 1999). The mass-diffusivity Dp is a function of 
particle size (Table 1).
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Steady-state versions of these equations were solved on a 16-processor workstation (Dell 
Precision T7600, Intel Xeon 3.10 GHz, 64 GB of RAM) using Fluent™ 14. Fluent™ utilizes 
the finite volume method to solve the differential equations numerically. The segregated 
solver with SIMPLEC pressure-velocity coupling and second-order upwind discretization 
were utilized. Since the physical properties of the air-particle mixture are assumed constant, 
an uncoupled solution strategy was employed, namely the flow field was obtained first and 
then the convection-diffusion equation was solved.
The boundary conditions for the flow simulations were (a) inlet pressure = 0 at the nostrils, 
(b) no-slip at the walls, and (c) outlet pressure set to a negative value such that the desired 
airflow rate (15 L/min, 22.5 L/min, or 30 L/min) was reached. For the nanoparticle transport 
simulations, the concentration of nanoparticles at the nostril was set to unity (Cp|nostrils = 1), 
while the concentration was set to 0 at the walls (Cp|wall = 0). For the calculation of wall 
fluxes, the simulation results were re-scaled for an inlet nanoparticle concentration of 160 
μg/m3, which is the atmospheric nanoparticle concentration used by Oberdorster et al (2004) 
in their experimental investigation of nanoparticle deposition in the rat.
Fluent™ does not provide the option of plotting nanoparticle flux (equivalent to nanoparticle 
deposition; flux = (−Dp∇Cp)wall) at the domain walls. Therefore, a User-Defined Function 
(UDF) was used to make the nanoparticle flux data available as a User-Defined Memory 
Variable so that wall fluxes could be visualized and hotspots of nanoparticle deposition 
described. The UDF also reported the fraction of nanoparticles deposited in each of the 2 
epithelium types (olfactory vs. non-olfactory), so that olfactory deposition could be 
quantified. The olfactory deposition obtained via the UDF was confirmed by typing “report 
species” in Fluent’s Text User Interface (TUI).
APPENDIX B
To gain insight into the different nanoparticle deposition patterns in humans and rats, let us 
calculate the average olfactory dose as a function of the inhalation rate and olfactory surface 
area. Conservation of mass requires that
where Øinlet, Øoutlet, and Øwall (units of kg/s) are respectively the mass fluxes of 
nanoparticles through the nostrils (inlet), nasopharynx (outlet), and nasal walls, QV (units of 
m3/s) is the volumetric airflow rate, and cinlet and coutlet (units of kg/m3) are respectively the 
nanoparticle concentrations at the nostrils and nasopharynx. Thus, the average wall flux per 
unit surface area (Ø̄nose) is given by
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where SA is the total nasal surface area. Using the definition of total deposition efficiency (η 
= 1 − coutlet/cinlet), the average wall flux in the nasal cavity can be written as
Similarly, the average wall flux per unit surface area in the olfactory region (Ø ̄olf) is
where ηO is the olfactory deposition efficiency and SAO is the olfactory surface area.
The above equations, in combination with the total deposition [η = η(QV, SA)] and olfactory 
deposition [ηO = ηO(QV, SAO)] derived from CFD simulations, allow us to compare the 
average nanoparticle doses in rats and humans. For example, based on the minute volumes 
of humans and rats (  and ), the total nasal surface 
area of the human and rat nasal models (SAhuman = 201.6 cm2 and SArat = 18.3 cm2), and the 
total deposition efficiency of 5 nm particles in humans and rats (ηhuman = 0.128 and ηrat = 
0.473), we estimate that for 5 nm particles the average nasal dose per unit surface area is 
higher in rats than in humans:
In contrast, we estimate that the average olfactory dose per unit surface area is higher in 
humans than in rats for 5 nm particles:
where the olfactory areas (  and ) and olfactory 
depositions of 5 nm particles (  and ) were used. These results 
illustrate that the average olfactory dose (per unit surface area) can be higher in humans than 
in rats, despite the fact the average nasal dose (per unit surface area) is higher in rats than in 
humans.
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Figure 1. Lateral view of computational models of the human nasal passages
Models 1A, 1B, and 1C represent the same nasal geometry, but with olfactory regions (dark 
gray) of different sizes. Model 2 represents the nasal anatomy of a different individual. It 
was used for validating our computational methods because several in vitro experiments and 
CFD simulations in the literature were based on this nasal geometry (see text for details).
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Figure 2. Deposition efficiency of inhaled nanoparticles in a human nasal cavity model (Model 
1A)
Symbols correspond to simulation results, while lines depict fitted curves.
Garcia et al. Page 18













Figure 3. Olfactory fraction of total nasal deposition in a human nasal cavity model (Model 1A)
Symbols correspond to simulation results, while lines depict fitted curves.
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Figure 4. Olfactory deposition efficiency in a human nasal cavity model (Model 1A)
Symbols correspond to simulation results, while lines depict fitted curves.
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Figure 5. Deposition patterns of 3-nm and 30-nm particles in the human nasal cavity for a 15 
L/min inhalation rate
While 3-nm particles deposit preferentially in the anterior nose, 30-nm particles deposit 
more uniformly in the nasal passages. The atmospheric nanoparticle concentration was 160 
μg/m3, which is the experimental atmospheric concentration in Oberdorster et al. (2004). 
Colormap scale: fmax = 1.3 × 10−6 μg/s.mm2.
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Figure 6. Dose of nanoparticles deposited in the human nasal cavity averaged along the 
perimeter of coronal cross sections and plotted as a function of the distance from the nostrils
The atmospheric nanoparticle concentration was 160 μg/m3, which is the experimental 
atmospheric concentration in Oberdorster et al. (2004). Curves are shown for airflow rates of 
15L/min, and particles sizes of 3 nm and 30 nm.
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Figure 7. Effect of varying the olfactory surface area on estimates of olfactory deposition
All models have the same geometry (Figure 1), except for variations in the olfactory surface 
area. (A) Olfactory deposition efficiency of 1–100 nm particles. (B) The ratio of olfactory 
deposition efficiency in Model 1B to olfactory deposition efficiency in Model 1A is 
approximately 0.50, which is the ratio between their olfactory surface areas. Similarly, the 
ratio of olfactory deposition efficiency in Model 1C to Model 1A is approximately 2.0, 
which is the ratio between their olfactory surface areas. The olfactory surface areas in 
Models 1A, 1B, and 1C are 11.2 cm2, 5.6 cm2, and 22.0 cm2, respectively.
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Figure 8. Total deposition efficiency of inhaled nanoparticles in the human nasal cavity (Model 
2) for a 10 L/min steady-state inhalation rate
(A) In vivo and in vitro experimental data from the literature compared to our computational 
results. (B) Computational studies from the literature compared to our results.
References: (Cheng et al., 1996; Cheng et al., 1995; Cheng et al., 1996; Ge et al., 2012; 
Ghalati et al., 2012; Kelly et al., 2004b; Shi et al., 2008; Swift et al., 1992; Xi & Longest, 
2008; Zamankhan et al., 2006).
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Figure 9. Nanoparticle deposition in the nasal cavity and olfactory region of humans and rats at 
rest (breathing rate = 15 L/min in humans and 0.58 L/min in rats)
(A) Total nasal deposition efficiency. (B) Olfactory deposition efficiency. (C) Rat-to-human 
ratio of nasal deposition efficiency and olfactory deposition efficiency. (D) Number of 
particles deposited in the olfactory region (olfactory dose) for an atmospheric concentration 
of 10,000 particles/cm3, assuming an uniform particle distribution in the 1–100nm range. 
Data for rats taken from Garcia and Kimbell (2009).
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Table 1
Diameter (dp) and diffusivity (Dp) of the nanoparticles used in the simulations. The 10 particle sizes were 
chosen so that log(dp) is uniformly spaced. The particle diffusivities were calculated according to the 
equations in Hinds (1999).
Particle diameter (nm) Particle diffusivity (cm2/s)
1.00 5.32 × 10−2
1.67 1.91 × 10−2
2.78 6.91 × 10−3
4.64 2.49 × 10−3
7.74 9.04 × 10−4
12.92 3.29 × 10−4
21.54 1.21 × 10−4
35.94 4.52 × 10−5
59.95 1.73 × 10−5
100.00 6.94 × 10−6
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